Why Is NOVAVAX INC (NVAX) Stock Up Today?

Novavax Inc. (NVAX) shares rose 12.94% to $12.44 on Thursday, driven by renewed market anxiety over a suspected pneumonic plague outbreak in Russia. The biotechnology firm, which develops vaccines and therapeutics, saw its stock surge as investors reassessed its potential role in addressing emerging infectious disease threats.

What Happened

The primary catalyst for the move was the report of a suspected pneumonic plague case in Siberia, which triggered a broader rally in vaccine and biotech stocks. Novavax, along with peers Moderna and Vaxcyte, experienced significant price appreciation in response to the news. The company’s recent Q2 2026 earnings call also provided context for its current financial position, though the immediate price action was dominated by the geopolitical and health-related headlines.

Despite the sharp intraday gain, analyst sentiment remains mixed. Bank of America raised its price target on NVAX to $8 from $7, while Citi downgraded the stock from Buy to Neutral. These actions highlight a divergence between short-term speculative interest and long-term fundamental assessments.

What The Data Shows

The stock opened at $11.07, a modest 0.5% gap above the previous close of $11.01. Trading volume reached 5.1 million shares, which is at the 3-month daily average level. The session high of $12.77 was recorded at 10:00 AM ET, while the low of $11.02 occurred early in the session at 9:25 AM ET.

Fundamental metrics indicate that Novavax remains unprofitable, with a trailing twelve-month EPS of -$1.52 and a net margin of -59.9%. Revenue has declined 61.6% over the same period. The company’s market cap stands at $1.9 billion, and its beta of 2.43 suggests high volatility relative to the broader market. The stock is currently trading within its 52-week range of $6.20 to $13.38. Over the last eight sessions, the stock had only moved 1.8% prior to today’s spike.

What To Watch

Investors will monitor how the market digests the plague-related headlines and whether the stock can sustain its gains above the $12.44 level. Analyst coverage will remain a key factor, particularly as firms like Citi and Bank of America adjust their ratings and price targets in response to the shifting risk landscape.